Open AccessPembrolizumab (Keytruda)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.110
Subject(s) - pembrolizumab , microsatellite instability , medicine , colorectal cancer , oncology , cancer , immunotherapy , microsatellite , allele , biochemistry , chemistry , gene
CADTH recommends that Keytruda (pembrolizumab) should be reimbursed as monotherapy for the first-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer if certain conditions are met.
Keytruda should only be reimbursed if prescribed by clinicians with experience in immuno-oncology and treating colorectal cancer, and if the price of the drug is reduced.
Keytruda should only be covered to treat patients who have not received prior treatment for metastatic MSI-H/dMMR colorectal cancer and have a good performance status at the start of treatment with pembrolizumab.